Fort Worth, Texas – – September 20, 2026 -- IWP Capital, LLC said it will vote FOR Proposal 6 at FedEx Corporation's (NYSE: FDX) annual meeting on September 28, 2026, pressing the board to disclose how it manages legal exposure tied to shipping mail-order abortion drugs.
IWP Capital co-filed the proposal with the Catholic Diocese of Fort Worth
The measure, titled "Report on Risks Related to Distributing Abortion Drugs," appears in the Stockholder Proposals section of FedEx's 2026 proxy statement beginning on page 104. It is precatory, asking FedEx's board to issue a report within one year, at reasonable cost, detailing how it oversees legal, regulatory, and reputational risk linked to transporting drugs such as mifepristone. The proposal does not seek to halt shipments of any lawful product or mandate package inspections.
Comstock Act enforcement uncertainty drives the risk case
IWP Capital CEO Sam Saladino said the firm is asking a board that emphasizes risk oversight to explain how it is preparing for a criminal statute whose enforcement remains unsettled. "Legal uncertainty of this magnitude is itself a material risk," Saladino said, citing that reasoning as the basis for the vote.
Investor pressure runs in both directions on the issue
IWP Capital noted that reputational scrutiny comes from two sides: investors pushing for continued drug-shipment access and faith-based coalitions raising legal-risk concerns. The firm argues this dual pressure gives FedEx's board a governance rationale to formally document its risk-oversight process. IWP Capital is encouraging fellow shareholders to review Proposal 6 ahead of the September 28 vote.